- XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
- October 19, 2025
- Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
- October 19, 2025
- PADCEVTM Plus KEYTRUDATM, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
- October 18, 2025
- TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
- October 14, 2025
- Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
- October 13, 2025
- Pfizer Declares Fourth-Quarter 2025 Dividend
- October 09, 2025
- Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
- September 30, 2025
- Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
- September 25, 2025
- Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
- September 23, 2025
- Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
- September 22, 2025
- Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
- September 08, 2025
- Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
- August 27, 2025
- PADCEVTM Plus KEYTRUDATM Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
- August 12, 2025
- Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
- August 05, 2025
- Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
- July 25, 2025
- Pfizer Completes Licensing Agreement with 3SBio
- July 24, 2025
- XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
- July 10, 2025
- Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZITM in Hemophilia A or B with Inhibitors
- June 26, 2025
- Pfizer Declares Third-Quarter 2025 Dividend
- June 25, 2025
- Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
- June 25, 2025
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- June 02, 2025
- Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
- May 31, 2025
- Pfizer's BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
- May 30, 2025
- Astellas and Pfizer's XTANDITM (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
- May 22, 2025
- Pfizer Enters into Exclusive Licensing Agreement with 3SBio
- May 19, 2025
- Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
- April 29, 2025
- Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
- April 26, 2025
- Pfizer Announces 2025 Shareholder Meeting Preliminary Results
- April 24, 2025
- Pfizer Declares Second-Quarter 2025 Dividend
- April 23, 2025
- Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
- April 23, 2025
- ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
- April 16, 2025
- Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
- April 14, 2025
- Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
- April 10, 2025
- European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
- April 01, 2025